PARP inhibitors, based on the principle of “synthetic lethality,” have shown remarkable efficacy in BRCA-mutated ovarian cancer, with several drugs significantly extending the progression-free survival of patients, opening a new chapter in precision treatment. This evidence concerns the gene PARP1 and ovarian cancer.